Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3629
- Registration Number
- NCT02244268
Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: alpha-adrenergic blocker
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4561
- Registration Number
- NCT02244307
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Ascending doses of HYTRIN® capsules
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1993
- Registration Number
- NCT02244255
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Matching placebo capsule
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 153
- Registration Number
- NCT02245490
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®OCAS®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5775
- Registration Number
- NCT02245542
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02244203
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4150
- Registration Number
- NCT02244320
Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms
Phase 2
Completed
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02244281
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1060
- Registration Number
- NCT02245555
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2914
- Registration Number
- NCT02244216
© Copyright 2025. All Rights Reserved by MedPath